IRIS
TOGNOLINI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.399
AS - Asia 6.566
EU - Europa 6.514
SA - Sud America 954
AF - Africa 395
Continente sconosciuto - Info sul continente non disponibili 251
OC - Oceania 2
Totale 26.081
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.082
SG - Singapore 2.159
IT - Italia 1.999
CN - Cina 1.859
VN - Vietnam 1.102
FI - Finlandia 840
SE - Svezia 778
IE - Irlanda 753
BR - Brasile 738
DE - Germania 665
HK - Hong Kong 446
UA - Ucraina 331
FR - Francia 257
ZA - Sudafrica 250
BD - Bangladesh 232
GB - Regno Unito 228
NL - Olanda 188
TR - Turchia 186
IN - India 168
CA - Canada 162
RU - Federazione Russa 115
AR - Argentina 85
BE - Belgio 65
AT - Austria 64
MX - Messico 59
CI - Costa d'Avorio 56
ID - Indonesia 52
JP - Giappone 50
IQ - Iraq 45
EC - Ecuador 43
KR - Corea 37
PH - Filippine 37
RO - Romania 36
CZ - Repubblica Ceca 35
ES - Italia 32
TH - Thailandia 32
PK - Pakistan 28
PL - Polonia 25
CO - Colombia 23
VE - Venezuela 22
JO - Giordania 20
LT - Lituania 19
CM - Camerun 17
CR - Costa Rica 16
SA - Arabia Saudita 16
MA - Marocco 15
CL - Cile 14
HN - Honduras 13
JM - Giamaica 13
PA - Panama 13
TN - Tunisia 13
EG - Egitto 12
CH - Svizzera 11
UZ - Uzbekistan 11
AL - Albania 10
MY - Malesia 10
BO - Bolivia 9
EU - Europa 9
NP - Nepal 9
KE - Kenya 8
NI - Nicaragua 8
PY - Paraguay 8
AZ - Azerbaigian 7
DK - Danimarca 7
EE - Estonia 7
HU - Ungheria 7
KG - Kirghizistan 7
PE - Perù 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
BG - Bulgaria 6
GT - Guatemala 6
AE - Emirati Arabi Uniti 5
BH - Bahrain 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
KZ - Kazakistan 5
LB - Libano 5
NO - Norvegia 5
PS - Palestinian Territory 5
PT - Portogallo 5
SI - Slovenia 5
SN - Senegal 5
CW - ???statistics.table.value.countryCode.CW??? 4
GR - Grecia 4
HR - Croazia 4
IR - Iran 4
RS - Serbia 4
SC - Seychelles 4
SV - El Salvador 4
BY - Bielorussia 3
ET - Etiopia 3
OM - Oman 3
QA - Qatar 3
UY - Uruguay 3
AU - Australia 2
BB - Barbados 2
BS - Bahamas 2
CU - Cuba 2
CY - Cipro 2
Totale 25.814
Salva come PNG Salva come JPEG
Città #
Dallas 2.977
Singapore 1.141
Ashburn 975
San Jose 803
Dublin 745
Chandler 737
Santa Clara 620
Parma 553
Beijing 435
Ann Arbor 434
Hong Kong 416
Jacksonville 362
Ho Chi Minh City 355
Dearborn 309
Boardman 267
Council Bluffs 256
Hanoi 252
Johannesburg 238
Munich 234
New York 185
Los Angeles 179
Nanjing 156
Shanghai 154
Izmir 151
Milan 151
Helsinki 137
Princeton 130
Hefei 128
Lauterbourg 124
Wilmington 110
Bremen 107
Bologna 105
San Mateo 80
São Paulo 74
Buffalo 69
Toronto 65
Columbus 61
Washington 60
Shenyang 59
Brussels 58
Kunming 57
Moscow 57
Abidjan 56
Rome 54
Vienna 52
Modena 49
Hebei 48
Jinan 48
Nanchang 47
Guangzhou 43
Turku 43
Chicago 42
Frankfurt am Main 42
Haiphong 42
Tokyo 42
Seattle 41
Da Nang 40
Phoenix 38
London 35
Woodbridge 35
Bengaluru 34
Rio de Janeiro 33
Des Moines 32
Brescia 31
Montreal 31
Orem 31
Changsha 29
The Dalles 29
Tianjin 29
Jiaxing 28
Bangalore 27
Brooklyn 27
Seoul 27
Atlanta 25
Hangzhou 24
Jakarta 24
Nuremberg 24
Fremont 23
Houston 23
Reggio Emilia 23
Lubbock 21
Belo Horizonte 20
Boston 20
Brasília 20
Düsseldorf 20
Mexico City 20
Stockholm 20
Turin 20
Florence 19
Ottawa 19
Piacenza 19
Brno 18
Naples 18
North Bergen 18
Amman 17
Denver 17
Grafing 17
Amsterdam 16
Pune 16
Warsaw 16
Totale 16.288
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.729
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.706
Principi di farmacognosia e fitoterapia. Seconda edizione 812
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 308
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 288
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 275
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 271
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 270
Principi di farmacognosia e fitoterapia 266
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 265
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 262
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 248
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 234
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 234
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 233
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 228
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 227
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 226
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 214
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 213
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 209
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 208
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 207
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 205
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 204
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 203
A simple GC-MS method for the screening of betulinic, corosolic, maslinic, oleanolic and ursolic acid contents in commercial botanicals used as food supplement ingredients 202
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 200
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 198
Enhanced photosensitizing properties of protein bound curcumin 194
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 193
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 193
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 189
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 188
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 187
A photosensitizing fusion protein with targeting capabilities 186
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 183
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 183
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 181
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 181
inibitori eph-ephrin biodisponibili oralmente 180
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 179
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 178
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 177
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 177
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 176
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 175
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 171
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction 168
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 168
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 168
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 166
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 166
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 166
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 165
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 165
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 165
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 164
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 163
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 161
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 159
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 159
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 159
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 157
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 156
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 156
Structure activity relationship of new EphA2 ligands 154
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 154
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 154
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 153
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 151
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 151
Target-hopping: a useful approach to identify novel Eph receptor antagonists 149
Discovery of natural extracts interfering with EphA2-ephrinA1 system 149
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 147
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 146
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 145
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 144
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 144
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 142
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 141
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 140
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 138
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 138
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 138
Synthesis and Biological Evaluation of N-Pyrazolyl-N'-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis 137
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 137
6-amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. 136
Pharmacological screening of novel antiplatelet agents with analgesic activity 135
5-substituted derivatives of 6-amino-1,3-diphenyl-2-thioxo-2.3-dihydropyrimidin-4(1H9-one as a new class of potent inhibitors of interleukin 8-induced chemotaxis 134
Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice 134
Progress in 5H [1] benzopyrano[4,3-d]pyrimidin-5-amine series: “-methoxy derivatives effective as antiìplatelet agents with analgesic activity 132
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 132
Are we using the right pharmacological tools to target EphA4? 132
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 132
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 132
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 131
Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn’s sisease (CD) model 131
PHENYLPROPANOID RICH ESSENTIAL OILS AS POTENTIAL ANTITHROMBOTICS ENDOWED WITH GASTROPROTECTIVE EFFECTS 128
New insights into the pharmacological properties of potent antiplatelet 2-amino-benzo|d|isothiazol-3-one derivatives 128
Totale 21.516
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022746 0 0 0 100 41 35 81 87 59 74 57 212
2022/20232.958 330 302 157 237 320 333 64 162 876 43 96 38
2023/20241.195 68 75 32 45 91 229 117 82 60 111 118 167
2024/20254.051 127 197 275 214 398 429 232 242 539 373 360 665
2025/202610.671 730 1.326 2.863 736 1.003 467 869 276 1.107 661 355 278
2026/20271.711 285 408 506 512 0 0 0 0 0 0 0 0
Totale 26.081